Company Analysis
Sign in

Harmony Biosciences Holdings, Inc. (HRMY)

Nasdaq: HRMY · Pharmaceutical Preparations · Plymouth Meeting, PA · filing with the SEC since 2020
Full chart Alerts Compare
Grade7.0
◀ Past 8.4● Present 6.9▶ Future 5.6
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$868M+21.5%
Net income$159M+9.1%
Earnings per share$2.71+8.0%
Operating cash flow$348M+58.4%
Cash$753M+66.1%
Debt$144M-11.9%
Shareholders’ equity$870M+32.0%
Shares, diluted58.5M+1.2%
Return on equity18.2%
The recordfrom its filings
Filings in 202663
Newest filingNov 4 · 10-Q
Annual reportFeb 24, 2026
Quarterly reportNov 4, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$6.0M
Insider buys, 12 months$0.00
Patents granted4
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $989MNet income $179MCash from operations $323Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

The company now

Harmony Biosciences sells WAKIX, a daily pill for narcolepsy, a sleep disorder that causes extreme daytime sleepiness 1.

Net product revenue rose by $60.8 million, or 30.3 percent, in the three months ended 30 June 2026 2.

The company said unit shipments grew 26.5 percent and a 7 percent price increase added to that, partly offset by higher rebates of about 4.0 percent 2.

On 12 October 2026 the company announced that chief executive Jeffrey Dayno will be retiring effective 31 December 2026 3.

Chief operating officer Peter Anastasiou has been appointed to succeed him as chief executive from 1 January 2027 3.

The FDA's review of a new pitolisant tablet, Pitolisant GR, has a target decision date of 1 April 2027 2.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.

News

Nov 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 13, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 18, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton HRMY · research, not advice